Sihuan Pharmaceutical (0460) Announces Xuanzhu Biopharm (2575) Inclusion in Hang Seng Composite Index

Bulletin Express

Yesterday

Sihuan Pharmaceutical Holdings Group Ltd. (0460) announced that its non-wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (2575) has been included as a constituent stock of the Hang Seng Composite Index, effective 9 March 2026. This inclusion follows the quarterly review results of the Hang Seng Family of Indexes for the period ended 31 December 2025, as announced on 13 February 2026.

Xuanzhu Biopharm, which was listed on the Main Board of the Stock Exchange of Hong Kong on 15 October 2025, may meet the requirements to be eligible for trading under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. According to the announcement, this development is expected to enhance the company’s share liquidity, broaden its investor base, and bolster its investor recognition in the capital market.

Sihuan Pharmaceutical’s management highlighted that the market recognizes Xuanzhu Biopharm’s research focus in digestion, oncology, and non-alcoholic steatohepatitis, as well as the company’s innovative pipeline in both small-molecule chemistry and large-molecule biologics research. Sihuan Pharmaceutical will continue to prioritize its two core segments of medical aesthetics and innovative pharmaceuticals while supporting Xuanzhu Biopharm’s ongoing R&D efforts and commercialization capabilities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1196396808"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196396808\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1196396808?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-22 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196396808","market":"us","top_or_hot":-1,"title":"Sihuan Pharmaceutical (0460) Announces Xuanzhu Biopharm (2575) Inclusion in Hang Seng Composite Index","media":"Bulletin Express","content":"<p>Sihuan Pharmaceutical Holdings Group Ltd. (0460) announced that its non-wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (2575) has been included as a constituent stock of the Hang Seng Composite Index, effective 9 March 2026. This inclusion follows the quarterly review results of the Hang Seng Family of Indexes for the period ended 31 December 2025, as announced on 13 February 2026.</p>\n<p>Xuanzhu Biopharm, which was listed on the Main Board of the Stock Exchange of Hong Kong on 15 October 2025, may meet the requirements to be eligible for trading under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. According to the announcement, this development is expected to enhance the company’s share liquidity, broaden its investor base, and bolster its investor recognition in the capital market.</p>\n<p>Sihuan Pharmaceutical’s management highlighted that the market recognizes Xuanzhu Biopharm’s research focus in digestion, oncology, and non-alcoholic steatohepatitis, as well as the company’s innovative pipeline in both small-molecule chemistry and large-molecule biologics research. Sihuan Pharmaceutical will continue to prioritize its two core segments of medical aesthetics and innovative pharmaceuticals while supporting Xuanzhu Biopharm’s ongoing R&D efforts and commercialization capabilities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharmaceutical (0460) Announces Xuanzhu Biopharm (2575) Inclusion in Hang Seng Composite Index</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharmaceutical (0460) Announces Xuanzhu Biopharm (2575) Inclusion in Hang Seng Composite Index\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-22 18:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sihuan Pharmaceutical Holdings Group Ltd. (0460) announced that its non-wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (2575) has been included as a constituent stock of the Hang Seng Composite Index, effective 9 March 2026. This inclusion follows the quarterly review results of the Hang Seng Family of Indexes for the period ended 31 December 2025, as announced on 13 February 2026.</p>\n<p>Xuanzhu Biopharm, which was listed on the Main Board of the Stock Exchange of Hong Kong on 15 October 2025, may meet the requirements to be eligible for trading under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. According to the announcement, this development is expected to enhance the company’s share liquidity, broaden its investor base, and bolster its investor recognition in the capital market.</p>\n<p>Sihuan Pharmaceutical’s management highlighted that the market recognizes Xuanzhu Biopharm’s research focus in digestion, oncology, and non-alcoholic steatohepatitis, as well as the company’s innovative pipeline in both small-molecule chemistry and large-molecule biologics research. Sihuan Pharmaceutical will continue to prioritize its two core segments of medical aesthetics and innovative pharmaceuticals while supporting Xuanzhu Biopharm’s ongoing R&D efforts and commercialization capabilities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"","article_id":"1196396808","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196396808","pubTimestamp":1771755696,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sihuan Pharmaceutical Holdings Group Ltd. (0460) announced that its non-wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (2575) has been included as a constituent stock of the Hang Seng...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00460":"四环医药"},"translate_title":"四环医药(0460)公布轩竹生物(2575)纳入恒生综合指数","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"Sihuan Pharmaceutical Holdings Group Ltd. (0460) announced that its non-wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (2575) has been included as a constituent stock of the Hang Seng Composite Index, effective 9 March 2026. This inclusion follows the quarterly review results of the Hang Seng Family of Indexes for the period ended 31 December 2025, as announced on 13 February 2026.\nXuanzhu Biopharm, which was listed on the Main Board of the Stock Exchange of Hong Kong on 15 October 2025, may meet the requirements to be eligible for trading under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. According to the announcement, this development is expected to enhance the company’s share liquidity, broaden its investor base, and bolster its investor recognition in the capital market.\nSihuan Pharmaceutical’s management highlighted that the market recognizes Xuanzhu Biopharm’s research focus in digestion, oncology, and non-alcoholic steatohepatitis, as well as the company’s innovative pipeline in both small-molecule chemistry and large-molecule biologics research. Sihuan Pharmaceutical will continue to prioritize its two core segments of medical aesthetics and innovative pharmaceuticals while supporting Xuanzhu Biopharm’s ongoing R&D efforts and commercialization capabilities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}